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Introduction: Nonadherence to inhalation therapy is very common in patients with chronic 
obstructive pulmonary disease (COPD). Few data are available to support the role of community 
pharmacists in optimizing inhalation therapy in COPD patients. Since 2007, the Kitano Hospital 
and the Kita-ku Pharmaceutical Association have provided a network system for delivering cor-
rect inhalation techniques through certified community pharmacists. The effects of this network 
system on clinical outcomes in COPD patients were examined.
Methods: A total of 88 consecutive outpatients with COPD at baseline and 82 of those 4 years 
later were recruited from the respiratory clinic of Kitano Hospital Medical Research Institute. 
Measurements included the frequency of COPD exacerbations, patients’ adherence to inhala-
tion therapy using a five-point Likert scale questionnaire, and patients’ health status both prior 
to this system and 4 years later.
Results: Usable information was obtained from 55 patients with COPD at baseline, and from 
51 patients 4 years later. Compared with baseline values, a significant decrease was observed 
in the frequency of COPD exacerbations (1.5 ± 1.6 versus 0.8 ± 1.4 times/year, P = 0.017). 
  Adherence to the inhalation regimen increased significantly (4.1 ± 0.7 versus 4.4 ± 0.8, 
P = 0.024), but health status was unchanged. At 4 years, of 51 COPD patients, 39 (76%) patients 
who visited the certified pharmacies showed significantly higher medication adherence than 
those who did not (4.6 ± 0.6 versus 3.9 ± 1.0, P = 0.022).
Conclusion: The network system may improve COPD control and adherence to inhalation 
regimens.
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Introduction
Chronic obstructive pulmonary disease (COPD) represents a major public health problem 
in terms of prevalence, mortality, impaired quality of life, and economic costs. In addition 
to smoking cessation, inhalation therapy constitutes the mainstay of COPD management.1 
Recent large-scale, long-term, and landmark studies have reported that a combination 
of a long-acting β2 agonist (salmeterol) and inhaled corticosteroid (fluticasone) modify 
the long-term decline in lung function, and an inhaled long-acting anticholinergic agent 
(tiotropium) appears to reduce mortality in COPD patients.2,3 However, in practice, many 
COPD patients are nonadherent to inhalation therapy. Some studies have demonstrated 
that approximately 60% of COPD patients are nonadherent to their inhalation regimen.4–6 
Furthermore, many patients make a number of critical errors in using an inhaler device.7 
Nonadherence to inhaled medication in COPD may be related to poor prognosis. A recent 
study revealed that the mortality rate was more than twice among COPD patients who 
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were nonadherent to their inhalation regimen compared with 
those that were adherent, when adherence is defined as .80% 
use of prescribed medication.8
Factors that improve adherence to inhalation therapy in 
COPD have not been fully addressed. Our previous cross-
sectional study showed that instructions on inhalation tech-
nique repeatedly provided for COPD patients contribute to 
adherence to therapeutic regimens and a significant positive 
relationship between adherence to the inhalation regimen 
and health status was demonstrated.9
Since 2007, we have developed “A Network system for 
Providing Proper Inhalation Technique” (NEPPIT) aimed at 
providing an educational program for community pharma-
cists to offer repeated instruction in correct and consistent 
inhalation technique to patients. We have previously reported 
the effects of NEPPIT on community pharmacists and asthma 
patients.10 Briefly, during the 4-year study period, the com-
munity pharmacists who attended our educational program 
were in 70% of the 81 community pharmacies in the northern 
area of Osaka. As compared with baseline values, at 4 years 
after the introduction of NEPPIT, the number of pharmacies 
stocking the materials for instruction increased by 30%, the 
frequency of pharmacists’ instruction on inhalation therapy 
more than tripled, and the population of pharmacists who 
gave verbal instruction and physical demonstrations of inha-
lation technique increased by 30%, resulting in a 30% and 
60% reduction in the frequency of asthma exacerbations and 
emergency room visits, respectively, and improved adherence 
to inhalation therapy in asthma patients.10 This study aimed 
to evaluate the long-term effects of our network system on 
clinical outcomes in COPD patients.
Methods
Study design
A prospective, pre–post, nonequivalent group study was 
carried out between November 2006 and December 2010. 
In April 2007, a network system of community pharmacists 
instructing patients on the correct inhalation technique 
was implemented. The information concerning patients’ 
inhaler use was shared between prescribers and community 
  pharmacists. The clinical effects of this network system on 
the frequency of COPD exacerbations, patients’ adherence to 
inhalation therapy, and health-related quality of life (QOL) 
were examined at baseline and 4 years later.
Study subjects
Eighty-eight consecutive outpatients with COPD at baseline 
and 82 of those at 4 years who were referred to the   respiratory 
clinic of the Kitano Hospital Medical Research Institute 
were recruited. Subjects were eligible for participation in the 
study if they met the following criteria: (1) current or former 
smoker (.10 pack-years); (2) regular visits to the respiratory 
outpatient clinic every 1 to 3 months; (3) respiratory physician 
diagnosed COPD; (4) physician prescribed inhaled medicines 
(anticholinergic, β2 agonist, inhaled corticosteroid [ICS], and/
or combined inhaler device of ICS and β2 agonist for at least 
12 months); and (5) no change in COPD inhaler medication 
for 3 months. Patients’ data were obtained from their medical 
records. The diagnosis and staging of COPD were confirmed 
by the lung function criteria of the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) guideline.1 The 
patients who still smoked were referred to a smoking cessation 
outpatient service run within the hospital.
Informed consent was obtained from all participants, and 
the research protocol was approved by the ethics commit-
tee of the Kitano Hospital, at the Tazuke Kofukai Medical 
Research Institute.
System of nEPPIT
NEPPIT has been in place since April 2007 through 
cooperation between the Kitano Hospital and the Kita-ku 
Pharmaceutical Association, which consists of 81 commu-
nity pharmacies in the northern area of Osaka, Japan. The 
main component of this system is an educational program 
for community pharmacists aimed at providing correct 
and consistent inhalation technique to patients. Through 
the program, all pharmacists received general informa-
tion regarding the pathophysiology of asthma and COPD, 
inhaled medication such as anticholinergic, ICS, and β2 
agonists, adherence to inhalation therapy, and inhalation 
technique. This educational program emphasized correct 
inhaler technique through lectures, role-playing, and skills 
training for each inhaler device. We provided participants 
with materials for instruction, such as training inhalers with 
placebo and checklists for the inhalation technique of each 
device. After training, they were able to demonstrate and 
give instruction about the correct inhaler technique for all of 
the devices. Subsequently, they were certified and registered 
as inhalation technique instructors and were encouraged 
to instruct patients on proper inhaler technique at regular 
intervals (at least every 6 months). A pharmacy with certified 
pharmacist(s) was defined as a certified pharmacy. To keep 
up with new trends in inhalation therapy, the validity of this 
certificate was limited to 2 years, and certified pharmacists 
were encouraged to attend our further educational program 
within 2 years.
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COPD patients in the study were given a pocket-sized 
booklet with detailed instructions on correct inhaler use and 
answers to common questions and concerns that patients have 
about using inhalers. Prescribers asked patients to carry this 
booklet and show it to pharmacists for the purpose of check-
ing their inhaler technique. Certified pharmacists were to 
report the status of patients’ inhalation technique to prescrib-
ers using a checklist and entering comments in the booklet.
Outcome measurements
Questionnaire regarding inhalation therapy
The data collection was done by the staff of the outpatient 
clinic of the Kitano Hospital. Potential study participants were 
approached in the waiting room by the researcher and were 
invited to answer a questionnaire prior to their appointment. 
The medical clerks helped collect the data of questionnaire. 
The Self-Reported Medication Adherence Questionnaire 
was administered as described previously.9–13 This adherence 
questionnaire is an adaptation of a scale originally developed 
by Morisky et al.14,15 This scale consists of four questions 
pertaining to the use of inhaled controller medications. There 
were five response options for each   question. For example, 
for the question, “During the last 3 months, have you: 
(1) Been careless about using your inhaler?; (2) Ever forgot-
ten to use your inhaler?; (3) Ever stopped using your inhaler 
because you felt better?; (4) Used your inhaler less than your 
doctor prescribed because you felt better?” responses ranged 
from 1 to 5, with a score of 1 indicating “Most of the time,” 
a score of 3 indicating, “Some of the time,” and a score of 
5 indicating, “None of the time.”
The self-reported adherence score was calculated from 
the mean of the responses to the four questions. Higher 
scores reflected better adherence to the inhalation regimen. 
Previous research has demonstrated that self-reported adher-
ence assessed with this questionnaire correlates well with 
adherence determined by pharmacy claims data.11 Improper 
responses to these five questions were excluded from the 
analysis.
Health-related quality of life questionnaire
The St George Respiratory Questionnaire (SGRQ) was used 
to measure the health-related QOL of COPD patients.16,17 The 
responses to its 50 items can be aggregated into a total score 
and three subscores for symptoms (measuring distress caused 
by respiratory symptoms), activities (measuring the effect of 
disturbances to mobility and physical activity), and impacts 
(quantifying the psychosocial impact of the disease). Scores 
range from 0 to 100, with higher scores reflecting worse 
health status.16,17 The Japanese version of the SGRQ has been 
validated.18 The SGRQ and the adherence questionnaire were 
given to the patients on the same day.
COPD exacerbations
Information on the frequency of COPD exacerbations was 
obtained from the patients’ medical records in the 12 months 
preceding questionnaire administration. Exacerbation of 
COPD was defined as symptomatic deterioration (dyspnea, 
cough, sputum purulence/volume, or wheeze) that required 
treatment with oral corticosteroids and/or antibiotics or 
hospitalization.
Analysis
Values are expressed as means (± standard deviation). The 
data were analyzed using Stat View 5.0 (SAS Institute, 
Cary, NC, USA). Comparisons between groups were made 
with the Mann–Whitney U test, Fisher’s exact probability 
test, or the chi-square test for univariate analysis. A value of 
P , 0.05 indicated significance.
Results
Comparison of COPD patients’ 
characteristics at baseline and at 4 years
Of the 88 patients at baseline and the 82 patients at 4 years, 
55 (63%) and 51 (62%) responded with usable informa-
tion, respectively. There were no differences in age and sex 
between respondents and nonrespondents in each survey 
period (data not shown). No differences were found in age, 
sex, smoking status, frequency of patients’ clinic visits, dura-
tion of disease, period and frequency of inhaler use, type of 
inhaler, presence of comorbidities, taking of antipsychotic 
drugs, and prevalence of COPD stage between baseline val-
ues and at 4 years. Pulmonary function expressed as forced 
expiratory volume (FEV1) percent predicted value and FEV1/
forced vital capacity showed a tendency to be lower at 4 years 
compared with baseline values. At 4 years, 39 (76.4%) of 51 
patients visited the NEPPIT-certified community pharmacies 
at regular intervals, and the remaining 12 patients visited 
other pharmacies (Table 1).
Comparison of outcome measures  
at baseline and 4 years
Compared with baseline, 4 years after the start of the 
network system, there was a significant decrease in the 
frequency of COPD exacerbations (1.5 ± 1.6/year to 
0.8 ± 1.4/year, P = 0.017) and a significant increase in 
the proportion of COPD patients adherent to inhalation 
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therapy (4.1 ± 0.7 to 4.4 ± 0.8, P = 0.024), but there were no 
  significant   differences in SGRQ scores (Table 2).
Comparison of patient characteristics 
and outcomes between COPD patients 
who visited a certified pharmacy and 
those who did not (at 4 years)
There was a significantly higher medication adherence for 
patients who visited a certified pharmacy compared with 
those who did not (4.6 ± 0.6 versus 3.9 ± 1.0, P = 0.022) 
(Table 3). As for other items, there were no significant 
differences in patient characteristics and outcomes, includ-
ing frequency of COPD exacerbations and SGRQ scores, 
between those who visited a certified pharmacy and those 
who visited a usual care pharmacy.
Discussion
A prospective study measuring adherence to inhaled therapy, 
frequency of COPD exacerbations, and health status at 
baseline and 4 years later was carried out. Compared with 
baseline, a significant reduction in the frequency of COPD 
exacerbations and an improved adherence to inhalation 
therapy were demonstrated 4 years after the start of the 
NEPPIT system. At 4 years, 39 (76%) of 51 COPD patients 
regularly visited certified pharmacies in which pharmacists 
trained as inhalation instructors provided patients with proper 
inhalation technique at regular intervals. Patients who visited 
certified pharmacies showed a significantly better adherence 
to inhalation therapy than those who did not.
Many publications in the past decade have reported that 
well-trained pharmacists could enhance therapeutic outcomes 
in patients with asthma.19–25 The need to consider pharmacist 
interventions for COPD patients has also been highlighted. 
Some well-designed, randomized, controlled studies have 
reported the effects of pharmacist care for COPD patients. 
For example, a study involving 173 COPD patients evalu-
ated an educational program focused on self-management 
administered by a clinical pharmacist. During the 12-month 
Table 1 Comparison of patients’ characteristics at baseline and 
4 years later
Baseline 4 years P-value
Patients (number) 55 51
Age (years) 69 (8) 69 (8) 0.90
Sex (female) 
Current smoking (yes) 
Frequency of clinic visits  
(per year)
15 
8 
8 (4–18)
7 
5 
7 (4–18)
0.09 
0.46 
0.86
Duration of disease (years) 
Period of inhaler use (years)
8.1 (10.6) 
5.9 (6.7)
7.4 (12.1) 
4.7 (6.0)
0.20 
0.26
Freq of inhaler use (per day) 2.4 (1.0) 1.9 (0.8) 0.18
Type of Inhaler 
(MDI:DPI:MDI + DPI)
18:18:19 12:27:12 0.11
Presence of comorbidities 
Taking of antipsychotic drugs 
Stage of COPD (1, 2, 3, 4) 
FEV1% predicted value (%) 
FEV1/FVC (%)
37 
13 
13, 30, 9, 3 
68.1 (16.0) 
56.3 (13.1)
36 
12 
10, 22, 15, 4 
61.0 (18.4) 
50.6 (14.4)
0.70 
0.99 
0.37 
0.052 
0.058
number of patients regularly  
visiting a certified pharmacy
– 39
Abbreviations:  MDI,  metered-dose  inhaler;  DPI,  dry  powder  inhaler;  FEV, 
forced expiratory volume; FVC, forced vital capacity; COPD, chronic obstructive 
pulmonary disease.
Table 2 Comparison of outcome measures in COPD patients at 
baseline and 4 years later
Baseline 4 years P-value
Patients (number) 55 51
Frequency of exacerbations  
(per year)
1.5 (1.6) 0.8 (1.4) 0.017
Overall mean adherence score 4.1 (0.7) 4.4 (0.8) 0.024
SgRQ scores
  Symptoms (0–100) 47.3 (25.9) 50.2 (21.2) 0.60
  Activities (0–100) 47.4 (21.9) 48.2 (26.2) 0.79
  Impacts (0–100) 31.3 (21.9) 28.8 (19.3) 0.78
  Total (0–100) 40.4 (20.1) 40.8 (20.8) 0.99
Abbreviations: COPD, chronic obstructive pulmonary disease; SgRQ, St george 
Respiratory Questionnaire.
Table  3  Comparison  of  COPD  patients’  characteristics  and 
outcomes  at  4  years  between  patients  visiting  the  certified 
pharmacy and those visiting the usual care pharmacy
Community pharmacy 4 years P-value
Certified Usual
Patients (number) 39 12
Age (years) 68.6 (8.2) 71.4 (8.0) 0.24
Sex (female) 
Current smoking (yes) 
Frequency of clinic visits (years) 
Duration of disease (years) 
Period of inhaler use (years) 
Freq of inhaler use (per day)
7 
4 
8.0 (3.3) 
8.3 (12.3) 
5.0 (6.5) 
2.2 (0.5)
0 
1 
7.4 (2.6) 
4.3 (3.1) 
3.3 (2.7) 
2.2 (0.7)
0.11 
0.84 
0.73 
0.76 
0.99 
0.93
Type of Inhaler 
(MDI:DPI:MDI + DPI) 
Presence of comorbidities 
Taking antipsychotic drugs
9:20:10 
10 
9
3:7:2 
4 
3
0.81 
0.60 
0.89
Stage of COPD (1, 2, 3, 4) 
FEV1% predicted value (%) 
FEV1/FVC (%) 
Freq of exacerbations (/year)
8, 14, 13, 4 
58.7 (19.0) 
48.5 (14.6) 
0.8 (1.4)
2, 8, 2, 0 
67.3 (15.8) 
56.8 (12.4) 
0.4 (1.2)
0.24 
0.16 
0.13 
0.34
Overall mean adherence score 4.6 (0.6) 3.9 (1.0) 0.022
SgRQ scores
  Symptoms (0–100) 51.6 (22.6) 45.1 (15.1) 0.43
  Activities (0–100) 51.4 (26.7) 37.5 (24.6) 0.16
  Impacts (0–100) 29.6 (17.5) 25.7 (26.2) 0.37
  Total (0–100) 42.5 (19.7) 34.3 (24.8) 0.25
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  MDI,  metered 
dose inhaler; DPI, dry powder inhaler; FEV, forced expiratory volume; FVC, forced 
vital capacity; SgRQ, St george Respiratory Questionnaire.
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study period, the patients allocated to the intervention group 
  demonstrated improvements in COPD knowledge, medication 
adherence, and humanistic outcomes assessed by the SGRQ, 
and reductions in both hospital admissions and emergency 
room visits when compared with control patients.26 Another 
study including 133 COPD patients showed that a single 
educational program provided by community pharmacists 
resulted in significant improvements in COPD knowledge, 
medication adherence, medication beliefs, and reduction in 
hospital admission rates in intervention patients when com-
pared with a control group between baseline and 6 months 
later.27 Thus, community pharmacists are well positioned to 
perform medication- and wellness-related interventions that 
can improve patient outcomes. The short-term effectiveness 
of an educational program for community pharmacists in 
improving clinical outcomes of COPD patients has been 
established, but long-term effects remain a challenge. The 
strength of the present study was the long-term design in 
order to confirm the clinical outcomes of the network system 
in COPD patients.
The NEPPIT system contributed to significant improve-
ment in medication adherence and reduction in COPD exac-
erbation rates 4 years after it was started. When considering 
the reason why this system affects clinical outcomes in 
COPD patients, one possible explanation is improving the 
skill of pharmacists’ instruction on inhalation technique. As 
we previously reported, NEPPIT improved the quality and 
quantity of pharmacists’ instruction, such as more pharmacies 
stocking the materials for instruction and more pharmacists 
giving verbal instructions and physical demonstrations of 
inhalation technique, resulting in improved clinical outcomes 
in asthma patients.10 Similarly, improvements in community 
pharmacists’ instruction seemed to be reflected in better 
clinical outcomes in COPD patients. In the present study, at 
4 years, 76.5% of COPD patients regularly visited the certi-
fied community pharmacy, and the remaining patients visited 
uncertified pharmacies. Indeed, COPD patients with instruc-
tion from a certified pharmacist on inhalation technique 
showed significantly better adherence to inhalation therapy 
than patients visiting a usual care pharmacist. The other pos-
sible reason for the positive results is repeated instruction 
regularly provided by community pharmacists. Our previous 
preliminary cross-sectional study demonstrated that COPD 
patients who received repeated instruction on inhalation 
technique showed better medication adherence and better 
health status than those who did not receive instruction.9 
Based on these data, NEPPIT has emphasized the necessity 
of repeated instruction on proper inhaler technique at least 
every 6 months. The present study confirmed its clinical 
impact and effect 4 years after the start of the system.
As several studies reported, the beneficial effect of 
pharmaceutical intervention on health-related QOL remains 
controversial.27–30 The present study also failed to demonstrate 
improvement of health status on the SGRQ. It is not easy to 
interpret this result, but a more intensive program, such as 
promotion of physical activity and ventilatory support, might 
be needed to improve QOL.
The present study had some limitations. First, the 
sample size of the study was small. Second, patients were 
not randomized to usual or interventional care groups. In 
that setting, however, pharmacists would have to follow-up 
with control subjects as well as with intervention subjects 
and change their method of instruction accordingly, which 
may not be practical over a long-term study period. Third, 
the participants at baseline and those at 4 years were not 
equivalent; however, it seems difficult to follow the same 
group of participants over the long term because the ben-
eficial effects of a pharmaceutical intervention on clinical 
outcomes in COPD could have been masked by the nature 
of a progressive disease like COPD.
In conclusion, this study demonstrated the long-term 
effects of our network system focused on “providing patients 
with correct inhaler use” and “checking patients’ inhala-
tion technique at regular intervals” through community 
pharmacists. Our system resulted in improved adherence to 
inhalation therapy and a reduction in the frequency of exac-
erbations in COPD patients. Further research with a large 
number of participants is needed to confirm the validity of 
the NEPPIT system.
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